Akebia concludes CKD drug Phase 2a trial
The study was intended to investigate the safety, tolerability and pharmacokinetics of 28 days of repeat oral doses of AKB-6548 in a cohort of stage 3 and stage
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.